{
  "meta": {
    "title": "Hansen_Disease_Part_-_2",
    "url": "https://brainandscalpel.vercel.app/hansen-disease-part-2-61a24217.html",
    "scrapedAt": "2025-11-29T18:24:09.601Z"
  },
  "questions": [
    {
      "id": 16924,
      "choices": [
        {
          "id": 67656,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tuberculoid Leprosy</span></span></span></p>"
        },
        {
          "id": 67657,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lepromatous Leprosy </span></span></span></p>"
        },
        {
          "id": 67658,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Borderline Leprosy</span></span></span></p>"
        },
        {
          "id": 67659,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Borderline Lepromatous leprosy</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Histopathology of a tissue sample from a patient with leprosy is shown below. All the following are possibilities EXCEPT.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/1.jpg\" style=\"height:233px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q2362348",
      "question_audio": null,
      "question_video": null,
      "map_id": 16485,
      "difficulty_level": "intermediate",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A) Tuberculoid leprosy</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given image shows a <strong>Grenz zone or Band of Unna</strong>, which is a band of uninvolved <strong>papillary dermis </strong>that does not contain granulomas or inflammatory infiltrate. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Grenz zone is absent in <strong>Tuberculoid leprosy</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dermal granulomas</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">, which are collections of <strong>epithelioid cells</strong> with <strong>giant cells</strong>, are seen in <strong>tuberculoid leprosy</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The granulomas are elongated and typically follow <strong>neurovascular bundles</strong>, running <strong>parallel</strong> to the surface. The granulomas extend up to the <strong>epidermis,</strong> thereby obscuring the <strong>Grenz zone.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation</span></u></strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">:</span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">Lepromatous Leprosy</span><span style=\"font-size:12.0pt\"> &ndash; </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lepromatous leprosy represents the <strong>polar opposite</strong> of the leprosy spectrum with <strong>poor cell-mediated immunity</strong> leading to a <strong>multibacillary state</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lepromatous leprosy </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">exhibits the Grenz zone most obviously because there are not many <strong>granulomas</strong> to fill the empty spaces below the epidermis.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Virchow cells with globi</strong> as indicated in the image, which are large <strong>macrophages filled with mycobacteria</strong>, are a characteristic feature of <strong>lepromatous leprosy</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Additionally, it appears on the <strong>borderline spectrum</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Borderline Leprosy</span><span style=\"font-size:12.0pt\"> &ndash;</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Borderline leprosy falls within the <strong>middle of the leprosy spectrum</strong>, with histological features that can fluctuate between those seen in tuberculoid and lepromatous forms. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>can show a grenz zone</strong> and <strong>foamy macrophages,</strong> which makes it a possibility in this case.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Borderline Lepromatous leprosy</span><span style=\"font-size:12.0pt\"> &ndash; </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Borderline Lepromatous leprosy is a subtype of leprosy that falls between the <strong>lepromatous</strong> <strong>and tuberculoid</strong> forms. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It would show features of both, with <strong>numerous bacteria</strong> present as well as <strong>some immune response</strong> limiting the spread. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, the histological findings seen in the image could correspond to this type, making it a possible option.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>absence</strong> of a <strong>grenz zone</strong> in histopathological samples is associated with <strong>tuberculoid leprosy</strong>, while the <strong>presence</strong> of a <strong>grenz zone</strong> and <strong>Virchow cells </strong>with<strong> globi</strong> are indicative of <strong>lepromatous forms</strong> of the <strong>disease</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:</span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Rooks Textbook of Dermatology 9<sup>th</sup> Edition Page No. 28.5</span></span></strong></p>",
      "correct_choice_id": 67656,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16925,
      "choices": [
        {
          "id": 67660,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Multibacillary Leprosy cases need treatment with Multi Drug Therapy (MDT) for 12 Months</span></span></span></p>"
        },
        {
          "id": 67661,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dapsone acts as Anti Leprosy Medication by Inhibiting Folate Synthesis.</span></span></span></p>"
        },
        {
          "id": 67662,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lepromin Testing is used for Diagnosis of Leprosy</span></span></span></p>"
        },
        {
          "id": 67663,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Clofazimine causes Deposition of Crystals in Intestinal Mucosa</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All of the following are correct statements regarding management of Leprosy EXCEPT:</span></span></span></p>",
      "unique_key": "Q4916316",
      "question_audio": null,
      "question_video": null,
      "map_id": 16486,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">C) Lepromin Testing is used for Diagnosis of Leprosy</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lepromin test</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is useful to <strong>classify</strong> the <strong>lesions</strong> of <strong>leprosy patients</strong>, to <strong>assess</strong> the <strong>prognosis </strong><strong>&amp; response to treatment</strong>, to assess the <strong>resistance</strong> of individuals to leprosy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Multibacillary leprosy</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> cases need treatment with Multi Drug Therapy (MDT) for 12 months.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\">Revised Treatment Regimen of Leprosy: </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\">Same Drug Dosages and Regimens for both Paucibacillary Leprsoy &amp; Multibacillary Leprosy except Duration ; <strong>Paucibacillary Leprosy for 6 months &amp; Multibacillary Leprosy for 12 months.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/18/image_NLNztME.png\" style=\"height:262px; width:452px\" /></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dapsone:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dapsone (DDS)</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> has good<strong> oral absorption</strong>, is weakly bactericidal due to the inhibition of <strong>dihydropteroate synthase</strong>, which <strong>inhibits folate synthesis</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a part of multidrug therapy for leprosy.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adverse effects</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> of Dapsone are:</span></span></span></li>\r\n</ul>\r\n\r\n<ol style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hemolysis &amp; anemia</span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Psychosis</span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">DDS syndrome or 5-week dermatitis</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">- occurs <strong>5-6 weeks</strong> after starting dapsone, which presents with:</span></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:80px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Erythroderma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hepatosplenomegaly</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lymphadenopathy</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fever</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hepatitis</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Clofazimine</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has a weak <strong>bactericidal</strong> activity against <strong>mycobacterium leprae </strong>&amp; causes <strong>deposition</strong> of crystals in <strong>intestinal mucosa, liver, lymph nodes </strong>&amp;<strong> spleen.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other <strong>adverse effects</strong> of Clofazimine are:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Icthyosis </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">of skin.</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skin <strong>discoloration</strong> (red to purple black)</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Lepromin test</strong> is used to <strong>assess</strong> the <strong>type</strong> of <strong>immune response</strong> in <strong>leprosy</strong> and is not a diagnostic test, while <strong>Multi Drug Therapy</strong> for <strong>12 months</strong>, the mechanism of action of <strong>dapsone</strong>, and the side effects of <strong>clofazimine</strong> are important <strong>aspects</strong> of <strong>leprosy management.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref:</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Rooks Textbook of Dermatology 9<sup>th</sup> Edition Chapter 28 Page No. 28.1- 28.15</span></strong></span></span></p>",
      "correct_choice_id": 67662,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16927,
      "choices": [
        {
          "id": 67668,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Type 1 Lepra Reaction presents with new Red Painful Lesions</span></span></span></p>"
        },
        {
          "id": 67669,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Systemic Symptoms are a feature of Type 2 Lepra Reaction</span></span></span></p>"
        },
        {
          "id": 67670,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Type 2 Lepra Reaction is due to Immune Complex Deposition</span></span></span></p>"
        },
        {
          "id": 67671,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Steroids are Drug of Choice in both Type 1 &amp; 2 Lepra Reactions</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All of the following are correct statements regarding Reactions in leprosy EXCEPT:</span></span></span></p>",
      "unique_key": "Q9736630",
      "question_audio": null,
      "question_video": null,
      "map_id": 16488,
      "difficulty_level": "intermediate",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A) Type 1 Lepra Reaction presents with New Red Painful Lesions</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Type 2</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> lepra reaction is associated with <strong>Type III</strong> hypersensitivity reaction (<strong>Immune complex</strong> deposition) &amp; clinically it presents with <strong>new </strong>red painful lesions, and also <strong>systemic </strong>features like <strong>fever, arthralgias, anorexia, keratitis, iritis, nephritis, synovitis, orchitis.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/picture3.jpg\" style=\"height:564px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/2.jpg\" style=\"height:198px; width:400px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/3.jpg\" style=\"height:207px; width:400px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/picture5.jpg\" style=\"height:563px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In leprosy, <strong>Type 1 reactions</strong> involve <strong>inflammation</strong> of <strong>existing lesions</strong> rather than the appearance of new lesions, while <strong>Type 2 reactions</strong> may present with <strong>systemic symptoms</strong> and are related to <strong>immune complex</strong> deposition, with <strong>steroids</strong> being the <strong>treatment of choice</strong> for <strong>both types of reactions</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref:</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Rooks Textbook of Dermatology 9<sup>th</sup> Edition Chapter 28 Page No. 28.1- 28.16</span></strong></span></span></p>",
      "correct_choice_id": 67668,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35872,
      "choices": [
        {
          "id": 143283,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">1, 2</span></p>"
        },
        {
          "id": 143284,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">1, 2, 3</span></p>"
        },
        {
          "id": 143285,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">1, 3, 4</span></p>"
        },
        {
          "id": 143286,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">1, 2, 3, 4</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which diagnostic investigation is utilized to identify the condition characterized by a 40-year-old man displaying abrupt Erythematous Painful Lesions on the Trunk and Face, Joint Pain, and Glove and Stock Anesthesia?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">1. Nerve examination</span></p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">2. Skin biopsy</span></p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">3. Slit skin smear</span></p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">4. Mantoux test</span></p>",
      "unique_key": "Q7509309",
      "question_audio": null,
      "question_video": null,
      "map_id": 23070,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. B) 1, 2, 3</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The clinical scenario points to a case of <strong>leprosy</strong>. The diagnosis of this condition requires <strong>nerve examination, skin biopsy, </strong>and <strong>a slit skin smear</strong> (Option B - 1, 2, 3).</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The clinical presentation described suggests a condition called <strong>leprosy</strong> or <strong>Hansen's</strong> disease, which can cause <strong>skin lesions</strong>, <strong>nerve</strong> damage resulting in <strong>anaesthesia</strong>, and <strong>joint pain</strong>.</span></p></li></ul><ol><li><p style=\"margin-left:40px;text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Nerve examination</strong> - An essential part of the diagnosis of leprosy involves the <strong>examination</strong> of <strong>nerves</strong> for <strong>enlargement</strong> and <strong>tenderness</strong>, which can indicate <strong>nerve damage</strong> due to the disease.</span></p></li><li><p style=\"margin-left:40px;text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Skin biopsy</strong> - A biopsy of the <strong>affected skin</strong> can be taken and <strong>histologically</strong> examined for the presence of <strong>Mycobacterium leprae</strong>, the bacterium that causes <strong>leprosy</strong>.</span></p></li><li><p style=\"margin-left:40px;text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Slit skin smear</strong> - This test involves taking a sample from the skin (usually from the <strong>ear lobes</strong> or from lesions) and staining it for <strong>acid</strong>-<strong>fast bacilli</strong>, which is a characteristic of <strong>Mycobacterium leprae</strong>.</span></p></li></ol><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>The Mantoux Test</strong> (Option 4)</span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>Mantoux</strong> test is used to diagnose <strong>tuberculosis</strong>, not leprosy.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">It involves the <strong>Tuberculin Skin Test</strong> (<strong>TST</strong>) to detect Mycobacterium <strong>Tuberculosis</strong> Infection.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Mycobacterium Tuberculosis and Mycobacterium Leprae are <strong>both acid</strong>-<strong>fast</strong> Bacilli.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The Mantoux test is <strong>specific</strong> for <strong>TB</strong> and does <strong>not</strong> directly <strong>aid</strong> in the <strong>diagnosis</strong> of <strong>leprosy</strong></span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Characteristic clinical features of <strong>Hansenâ€™s Disease</strong> / <strong>Leprosy</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Mycobacterium leprae </strong>is the cause of the<strong> chronic granulomatous disease </strong>known as<strong> leprosy</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The<strong> typical incubation period </strong>for<strong> leprosy </strong>is<strong> 2 to 12 years.</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">It frequently manifests as a <strong>visible skin</strong> lesion, such as a <strong>hypopigmented</strong> or <strong>erythematous</strong> macule, or as a <strong>numb spot</strong> on the <strong>skin</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>face, buttocks, trunk, </strong>and<strong> extensor aspects</strong> of the limbs are frequently <strong>affected</strong> by <strong>lesions</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Skin, cutaneous, </strong>and<strong> peripheral nerves</strong>, as well as <strong>mucous</strong> <strong>membranes</strong>, are all <strong>impacted</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The Ulnar nerve followed by the <strong>posterior tibial nerve</strong>, median and <strong>lateral popliteal nerves</strong>, are the <strong>peripheral nerves</strong> that are most frequently <strong>affected</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The<strong> facial nerve </strong>is the<strong> cranial nerve </strong>that is involved<strong> most frequently.</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Both <strong>nerve function</strong> and <strong>hair growth</strong> are <strong>compromised</strong> by the <strong>lesions</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Burns </strong>or<strong> ulcers </strong>on the<strong> amputation limb </strong>may also be<strong> present </strong>in the<strong> patients.</strong></span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Classification Systems of Leprosy:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ridley-Jopling Classification</strong></span></p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Tuberculoid (TT)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Borderline tubercular (BT)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Borderline (BB)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Borderline lepromatous (BL)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Lepromatous (LL)</span></p></li></ul></li></ul><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>WHO Classification:</strong></span></p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Paucibacillary</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Multibacillary</span></p></li></ul></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Cardinal Signs </strong>for the<strong> Diagnosis </strong>of<strong> Leprosy:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/screenshot-2024-02-22-094332.jpg\" alt=\"\" width=\"1000\" height=\"306\"></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>presence</strong> of <strong>two</strong> of the <strong>three signs</strong> can establish the diagnosis of <strong>leprosy</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Other tests done for <strong>diagnosis</strong> of <strong>leprosy</strong> include <strong>nerve biopsy </strong>in<strong> pure neural leprosy </strong>and<strong> PGL-1 antibody </strong>in cases with<strong> low bacterial load</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Mantoux test </strong>is<strong> not </strong>useful<strong> </strong>in<strong> diagnosis </strong>of<strong> leprosy</strong>. This is the test which helps to explain the <strong>prognosis </strong>of leprosy.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The appropriate diagnostic investigations for a <strong>suspected case</strong> of <strong>leprosy</strong> include <strong>nerve</strong> examination, skin <strong>biopsy</strong>, and <strong>slit skin smear</strong> to detect the <strong>presence</strong> of <strong>Mycobacterium leprae</strong> and to <strong>assess</strong> the <strong>extent</strong> of <strong>nerve damage</strong>.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Ref:</u> Rooks Textbook of Dermatology- 9<sup>th</sup> Edition Chapter 28 Page No 28.1, 28.3, 28.12</strong></span></p><p><span style=\"font-size:12.0pt;\"><strong>Harrisons Principles of Internal Medicine, 21<sup>st</sup> Edition 1385, 1386, 1388</strong></span></p>",
      "correct_choice_id": 143284,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35875,
      "choices": [
        {
          "id": 143295,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stop MDT and Start Oral Steroids</span></span></span></p>"
        },
        {
          "id": 143296,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibiotics</span></span></span></p>"
        },
        {
          "id": 143297,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide</span></span></span></p>"
        },
        {
          "id": 143298,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue MDT and Add Oral Steroids</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a pregnant woman at 12 weeks of gestation, who is currently undergoing multidrug therapy (MDT) for leprosy, she now presents with type 2 lepra reaction. What is the preferred treatment for this patient?</span></span></span></p>",
      "unique_key": "Q7134361",
      "question_audio": null,
      "question_video": null,
      "map_id": 23071,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Continue MDT and Add Oral Steroids</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the management of leprosy, it is crucial to <strong>continue M</strong><strong>ulti Drug Therapy</strong> <strong>(MDT) </strong>to effectively treat the <strong>underlying infection </strong>caused by <strong>Mycobacterium Leprae.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>Type 2 lepra </strong>reaction, also known as <strong>Erythema Nodosum Leprosum (ENL), </strong>is a complex <strong>immunological reaction </strong>that occurs in <strong>Lepromatous and Borderline Lepromatous Leprosy</strong>, which can present with <strong>Painful Nodules</strong>, <strong>Fever, Malaise</strong>, and other <strong>Systemic </strong>symptoms.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral Steroids</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, such as <strong>Prednisone</strong>, are the treatment of choice for controlling <strong>Acute Inflammatory Complications </strong>associated with Type 2 Lepra Reaction. They help <strong>Reduce Inflammation </strong>and <strong>Immune</strong> response.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is important to manage the reaction <strong>without discontinuing </strong>the <strong>MDT</strong> to <strong>prevent </strong>the development of <strong>Drug Resistance </strong>and further progression of the disease.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Erythema Nodosum Leprosum (ENL)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a <strong>type 3 hypersensitive immune complex-mediated reaction</strong> that affects the <strong>skin, nerves, and other organs. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is typically r<strong>ecurrent</strong> and commonly observed in individuals with <strong>multibacillary</strong> leprosy. ENL may occur <strong>before treatment</strong>, <strong>during treatment</strong> or <strong>after</strong> completion of treatment.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is characterized by <strong>painful, erythematous nodules</strong> appearing on the extensor surfaces of the <strong>limbs and face.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a type 2 lepra reaction, <strong>systemic symptoms </strong>such as <strong>iritis, orchitis</strong>, and the appearance of <strong>fresh </strong>skin lesions can be observed.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Treatment includes:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High doses of <strong>glucocorticoids</strong> are frequently administered to all patients which assist in <strong>reducing</strong> the acute signs and symptoms of <strong>inflammation.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with lepra reactions, <strong>MDT is never discontinued</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only severe cases of type-2 lepra reaction or erythema nodosum Leprosum are treated with thalidomide.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thalidomide is <strong>gold standard for type II Lepra</strong> reaction, but it is <strong>NOT the Drug of Choice</strong> due to its <strong>cost</strong> factor &amp; also its <strong>Adverse drug reactions profile.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Type I &amp; II Lepra Reactions (ENL= Erythema Nodosum Leprosum): </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/screenshot-2024-02-22-094524.jpg\" style=\"height:406px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To manage a <strong>pregnant woman </strong>experiencing a <strong>type 2 lepra reaction</strong>, it is essential to <strong>continue the multidrug therapy (MDT)</strong> while adding <strong>oral steroids </strong>as an <strong>additional</strong> treatment.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Stop MDT and start oral steroids:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stopping MDT is <strong>not advisable</strong> because it can lead to the <strong>proliferation</strong> of <strong>Mycobacterium leprae</strong> and risk the development of <strong>drug resistance.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">Antibiotics:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>antibiotics</strong> are a <strong>part of MDT</strong> to treat the <strong>bacterial infection</strong>, they alone are <strong>not sufficient</strong> to address the <strong>acute inflammatory symptoms</strong> of a Type 2 lepra reaction.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Thalidomide<strong>:</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thalidomide is an <strong>effective treatment</strong> for <strong>Type 2 lepra reactions</strong> due to its <strong>potent anti-inflammatory</strong> properties.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, it is <strong>absolutely contraindicated</strong> in <strong>pregnant</strong> <strong>women</strong> due to its <strong>teratogenic effects</strong>, which can cause <strong>severe birth defects as seen in the below image</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/4.jpg\" style=\"height:545px; width:500px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Phocomelia </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>pregnant</strong> <strong>woman</strong> with <strong>leprosy</strong> who presents with a <strong>Type 2 lepra</strong> reaction, the preferred treatment is to <strong>continue multidrug therapy</strong> and <strong>add oral steroids</strong> to manage the <strong>acute inflammatory symptoms</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thalidomide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is c<strong>ontraindicated</strong> in pregnancy due to its <strong>teratogenicity.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span style=\"font-size:12.0pt\">:&nbsp; Rook&#39;s Textbook of Dermatology -9th Edition Chapter 28 Page No 28.16</span></strong></span></span></p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Harrison&rsquo;s Principles of Internal Medicine 21<sup>st</sup> Edition Page No 1387, 1390</span></span></strong></p>",
      "correct_choice_id": 143298,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35880,
      "choices": [
        {
          "id": 143315,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stop MDT give Thalidomide</span></span></span></p>"
        },
        {
          "id": 143316,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue MDT, Start Thalidomide</span></span></span></p>"
        },
        {
          "id": 143317,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stop MDT, Start Systemic Corticosteroids</span></span></span></p>"
        },
        {
          "id": 143318,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue MDT, Start Systemic Steroids</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a case where a patient undergoing Multi-Drug Therapy (MDT) experiences a deterioration of existing lesions and nerve complications, what course of action would you consider taking next?</span></span></span></p>",
      "unique_key": "Q6327792",
      "question_audio": null,
      "question_video": null,
      "map_id": 23072,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">D) Continue MDT, Start Systemic Steroids</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><strong><span style=\"font-size:12.0pt\"> D: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is the <strong>correct management</strong> for a leprosy patient with <strong>nerve damage</strong>, which is likely due to an <strong>immune reaction</strong> called a <strong>leprosy reaction</strong>. <strong>Systemic corticosteroids</strong> are used to control the <strong>inflammation</strong> and <strong>prevent</strong> further <strong>nerve damage</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MDT should be continued to <strong>treat</strong> the <strong>underlying infection</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The reason for selecting option D is that <strong>systemic corticosteroids</strong> are <strong>effective</strong> in treating <strong>acute nerve inflammation</strong> and can prevent <strong>further damage</strong> while <strong>continuing MDT </strong>ensures that the infection<strong> </strong>is<strong> adequately treated.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The situation described, where <strong>pre-existing lesions worsen </strong>during<strong> multi-drug therapy (MDT) </strong>for<strong> leprosy, indicates </strong>a<strong> type 1 lepra reaction</strong>. In managing this condition, the recommended approach would be to <strong>continue MDT while initiating systemic steroid treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Type 1 lepra reactions are marked by inflammation of existing skin lesions, <strong>leading to symptoms such as edema, redness, and pain.</strong> While <strong>ulcers</strong> are <strong>uncommon</strong>, the development of new lesions is <strong>exceptionally rare</strong>. Additionally, <strong>acute neuritis</strong> may occur, presenting with <strong>tenderness</strong> and <strong>impairment</strong> of <strong>both motor</strong> and <strong>sensory functions</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with<strong> lepra reactions, MDT </strong>is<strong> never discontinued</strong></span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>NSAIDs</strong> and <strong>oral steroids</strong> can be added to treat pain.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thalidomide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is considered the <strong>gold standard</strong> for treating severe cases of <strong>type-2 lepra reaction</strong> or <strong>erythema nodosum leprosum</strong>. However, it is <strong>not the Drug of Choice</strong> due to its <strong>high cost</strong> and <strong>potential</strong> for <strong>adverse drug reactions</strong>. In<strong> type II lepra reactions, </strong>patients may<strong> </strong>experience<strong> systemic symptoms </strong>such as<strong> iritis, orchitis</strong>,<strong> </strong>and<strong> the </strong>appearance of new<strong> skin lesions.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Type I &amp; II Lepra Reactions:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/screenshot-2024-02-22-094555.jpg\" style=\"height:309px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">(ENL = Erythema Nodosum Leprosum)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Stop MDT give thalidomide.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thalidomide is an <strong>immunomodulatory</strong> drug that may be used in certain conditions, like <strong>leprosy</strong> and its complications. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, <strong>stopping MDT is not recommended</strong> as it is crucial to continue the treatment of the primary disease. Thalidomide is <strong>not used as </strong>treatment for <strong>Type 1 lepra reaction in leprosy</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">Continue MDT, start thalidomide &ndash;<strong> </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While MDT should be continued, thalidomide is not typically used for nerve complications. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It&#39;s used <strong>primarily</strong> for severe or recurrent <strong>erythema nodosum leprosum (ENL) Type 2 Lepra eaction,</strong> which is an immune-mediated complication of leprosy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Stop MDT, start systemic corticosteroids</span><span style=\"font-size:12.0pt\"> &ndash; </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stopping MDT is not advised as the antibiotics in MDT are essential for <strong>treating</strong> the <strong>bacterial infection</strong> causing the <strong>disease</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The MDT should be continued to <strong>prevent</strong> the <strong>development</strong> of <strong>drug resistance</strong> and to <strong>adequately treat</strong> the <strong>underlying infection</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the case of <strong>nerve complications </strong>in a patient undergoing <strong>multi-drug therapy </strong>for conditions like <strong>leprosy</strong>, the appropriate course of action is to <strong>continue the anti-microbial therapy</strong> and start <strong>systemic steroids </strong>to manage the <strong>inflammatory</strong> reaction causing nerve damage.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rook&#39;s Textbook of Dermatology -9th Edition Chapter 28 Page No 28.5, 28.12, 28.16</span></span></strong></p>",
      "correct_choice_id": 143318,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35884,
      "choices": [
        {
          "id": 143331,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Packet 1 for 12 Months</span></p>"
        },
        {
          "id": 143332,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Packet 2 for 12 Months</span></p>"
        },
        {
          "id": 143333,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Packet 1 for 6 Months</span></p>"
        },
        {
          "id": 143334,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Packet 2 for 6 Months</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:14.0pt;\">A 35-year-old patient presents to the outpatient department with a satellite skin lesion. On examination, the patient has one hypopigmented lesion and one thickened nerve. The images of two blister packs are provided. Based on the WHO / NLEP Guidelines, which treatment is most appropriate for this patient?</span></p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_q7gUPBV.jpeg\" alt=\"A close-up of a packet\r\n\r\n\r\n\r\nDescription automatically generated\" width=\"243\" height=\"174\"></p>",
      "unique_key": "Q3085843",
      "question_audio": null,
      "question_video": null,
      "map_id": 23073,
      "difficulty_level": "difficult",
      "subjects_id": [
        18
      ],
      "solution": "<p><span style=\"font-size:10.5pt;\">The correct answer is <strong>B. Packet 2 for 12 months</strong>.</span></p><h3><span style=\"color:#1F3763;font-size:10.5pt;\">Explanation:</span></h3><p><span style=\"font-size:13.5pt;\"><strong>Latest Guidelines for Leprosy: NLEP = WHO (from April 1, 2025)</strong></span></p><p>As of <strong>April 1, 2025</strong>, <strong>India's NLEP has aligned completely with WHO guidelines</strong> for the <strong>diagnosis and treatment of leprosy</strong>. This means that the <strong>same criteria and drug regimens</strong> are now followed globally and in India.</p><p>&nbsp;</p><figure class=\"table\"><table><tbody><tr><td style=\"background-color:#4472C4;border:1.0pt solid #4472C4;height:21.0pt;padding:.75pt;width:494.25pt;\" colspan=\"3\"><span style=\"color:white;font-size:9.0pt;\"><strong>World health organization (WHO)&nbsp;</strong></span></td></tr><tr><td style=\"background-color:#D9E2F3;border-bottom-style:solid;border-color:#8EAADB;border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:28.5pt;padding:.75pt;width:288.75pt;\"><span style=\"color:black;font-size:9.0pt;\"><strong>Cardinal features</strong></span></td><td style=\"background-color:#D9E2F3;border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:28.5pt;padding:.75pt;width:105.0pt;\"><span style=\"color:black;font-size:9.0pt;\"><strong>Paucibacillary&nbsp;</strong></span></td><td style=\"background-color:#D9E2F3;border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:28.5pt;padding:.75pt;width:100.5pt;\"><span style=\"color:black;font-size:9.0pt;\"><strong>Multibacillary&nbsp;</strong></span></td></tr><tr><td style=\"border-bottom-style:solid;border-color:#8EAADB;border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:35.25pt;padding:.75pt;width:288.75pt;\"><span style=\"font-size:9.0pt;\"><strong>Skin: Hypopigmented/ Hypoanesthetic patches</strong></span></td><td style=\"border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:35.25pt;padding:.75pt;width:105.0pt;\"><span style=\"font-size:9.0pt;\">1-5&nbsp;</span></td><td style=\"border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:35.25pt;padding:.75pt;width:100.5pt;\"><span style=\"font-size:9.0pt;\">â‰¥6</span></td></tr><tr><td style=\"background-color:#D9E2F3;border-bottom-style:solid;border-color:#8EAADB;border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:34.5pt;padding:.75pt;width:288.75pt;\"><span style=\"color:black;font-size:9.0pt;\"><strong>Nerves thickened +/- tenderness</strong></span></td><td style=\"background-color:#D9E2F3;border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:34.5pt;padding:.75pt;width:105.0pt;\"><span style=\"color:black;font-size:9.0pt;\">No&nbsp;</span></td><td style=\"background-color:#D9E2F3;border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:34.5pt;padding:.75pt;width:100.5pt;\"><span style=\"color:black;font-size:9.0pt;\">â‰¥1&nbsp;</span></td></tr><tr><td style=\"border-bottom-style:solid;border-color:#8EAADB;border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:20.25pt;padding:.75pt;width:288.75pt;\"><span style=\"font-size:9.0pt;\"><strong>SSS AFB</strong></span></td><td style=\"border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:20.25pt;padding:.75pt;width:105.0pt;\"><span style=\"font-size:9.0pt;\">Absent&nbsp;</span></td><td style=\"border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:20.25pt;padding:.75pt;width:100.5pt;\"><span style=\"font-size:9.0pt;\">Present&nbsp;</span></td></tr></tbody></table></figure><p><span style=\"font-size:10.5pt;\"><i>*If a case has any one of the three features suggestive of MB, he/she is classified as MB.</i></span></p><p>&nbsp;</p><p><span style=\"font-size:13.5pt;\"><strong>Treatment Regimen: WHO &amp; NLEP (Post April 1st 2025)</strong></span></p><p><span style=\"font-size:10.5pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_TvF6QJv.png\" alt=\"A chart of medication\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nDescription automatically generated with medium confidence\" width=\"337\" height=\"173\"></span></p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_lvloMqq.png\" alt=\"Health &amp; Family Welfare Department, Government of Tamil Nadu\" width=\"184\" height=\"239\"></p><p><span style=\"font-size:10.5pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_LCh7rB3.png\" width=\"463\" height=\"250\"></span></p><p>&nbsp;</p><p>&nbsp;</p><h3><span style=\"color:#1F3763;font-size:10.5pt;\">Other Options:</span></h3><p style=\"margin-left:18.0pt;\"><span style=\"font-size:10.5pt;\"><strong>Option A: Packet 1 for 12 months:</strong>&nbsp;</span></p><p style=\"margin-left:18.0pt;\"><span style=\"font-size:10.5pt;\">This packet was used for the treatment of paucibacillary leprosy according to old guidelines of NLEP, which is not suitable for a patient with multibacillary leprosy.</span></p><p style=\"margin-left:18.0pt;\"><span style=\"font-size:10.5pt;\"><strong>Option C: Packet 1 for 6 months:&nbsp;</strong></span></p><p style=\"margin-left:18.0pt;\"><span style=\"font-size:10.5pt;\">This packet was used for the treatment of paucibacillary leprosy according to old guidelines of NLEP, which is not suitable for a patient with multibacillary leprosy.</span></p><p style=\"margin-left:18.0pt;\"><span style=\"font-size:10.5pt;\"><strong>Option D Packet 2 for 6 months:</strong>&nbsp;</span></p><p style=\"margin-left:18.0pt;\"><span style=\"font-size:10.5pt;\">Although Packet 2 contains the correct medications, the treatment duration of 6 months is insufficient for multibacillary leprosy according to WHO guidelines, which recommends 12 months.</span></p><p>&nbsp;</p><p>OLD NLEP GUIDELINES to diagnose Leprosy&nbsp;</p><figure class=\"table\"><table><tbody><tr><td style=\"background-color:#4472C4;border:1.0pt solid #4472C4;height:21.0pt;padding:.75pt;width:469.5pt;\" colspan=\"3\"><span style=\"color:white;font-size:9.0pt;\"><strong>National Leprosy Eradication Programme (NLEP)&nbsp;</strong></span></td></tr><tr><td style=\"background-color:#D9E2F3;border-bottom-style:solid;border-color:#8EAADB;border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:28.5pt;padding:.75pt;width:281.9pt;\"><span style=\"color:black;font-size:9.0pt;\"><strong>Cardinal features</strong></span></td><td style=\"background-color:#D9E2F3;border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:28.5pt;padding:.75pt;width:91.3pt;\"><span style=\"color:black;font-size:9.0pt;\"><strong>Paucibacillary&nbsp;</strong></span></td><td style=\"background-color:#D9E2F3;border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:28.5pt;padding:.75pt;width:96.3pt;\"><span style=\"color:black;font-size:9.0pt;\"><strong>Multibacillary&nbsp;</strong></span></td></tr><tr><td style=\"border-bottom-style:solid;border-color:#8EAADB;border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:35.25pt;padding:.75pt;width:281.9pt;\"><span style=\"font-size:9.0pt;\"><strong>Skin: Hypopigmented/ Hypoanesthetic patches</strong></span></td><td style=\"border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:35.25pt;padding:.75pt;width:91.3pt;\"><span style=\"font-size:9.0pt;\">1-5&nbsp;</span></td><td style=\"border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:35.25pt;padding:.75pt;width:96.3pt;\"><span style=\"font-size:9.0pt;\">â‰¥6</span></td></tr><tr><td style=\"background-color:#D9E2F3;border-bottom-style:solid;border-color:#8EAADB;border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:34.5pt;padding:.75pt;width:281.9pt;\"><span style=\"color:black;font-size:9.0pt;\"><strong>Nerves thickened +/- tenderness</strong></span></td><td style=\"background-color:#D9E2F3;border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:34.5pt;padding:.75pt;width:91.3pt;\"><span style=\"color:black;font-size:9.0pt;\">No or 1 nerve</span></td><td style=\"background-color:#D9E2F3;border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:34.5pt;padding:.75pt;width:96.3pt;\"><span style=\"color:black;font-size:9.0pt;\">&gt;1&nbsp;</span></td></tr><tr><td style=\"border-bottom-style:solid;border-color:#8EAADB;border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:20.25pt;padding:.75pt;width:281.9pt;\"><span style=\"font-size:9.0pt;\"><strong>SSS AFB</strong></span></td><td style=\"border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:20.25pt;padding:.75pt;width:91.3pt;\"><span style=\"font-size:9.0pt;\">Absent&nbsp;</span></td><td style=\"border-bottom:1.0pt solid #8EAADB;border-left-style:none;border-right:1.0pt solid #8EAADB;border-top-style:none;height:20.25pt;padding:.75pt;width:96.3pt;\"><span style=\"font-size:9.0pt;\">Present&nbsp;</span></td></tr></tbody></table></figure><p>&nbsp;</p><p>OLD NLEP GUIDELINES to treat Leprosy&nbsp;</p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_XtDaahO.png\" alt=\"A chart of drugs and drugs\r\n\r\nAI-generated content may be incorrect.\" width=\"468\" height=\"243\"></p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_oiKCOxp.png\" alt=\"A green label with black circles and white text\r\n\r\nAI-generated content may be incorrect.\" width=\"468\" height=\"257\"></p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_EcNy2Kg.png\" alt=\"A close-up of pills\r\n\r\nAI-generated content may be incorrect.\" width=\"416\" height=\"229\"></p><p><span style=\"font-size:10.5pt;\"><i><strong>Educational objective:</strong></i></span></p><ul style=\"list-style-type:disc;\"><li>As of <strong>April 1, 2025</strong>, <strong>NLEP follows WHO guidelines</strong> for both <strong>diagnosis and treatment</strong>.</li><li>Classification is based on <strong>skin lesions</strong>, <strong>nerve involvement</strong>, and <strong>skin smear</strong>.</li><li><span style=\"font-size:10.5pt;\">For a patient with <i><strong>multibacillary leprosy</strong></i>, characterized by <i><strong>one or more thickened nerves</strong></i> and <i><strong>multiple skin lesions</strong></i>, the appropriate treatment is with a regimen containing <i><strong>rifampicin, clofazimine, and dapsone (Packet 2)</strong></i> for a duration of <i><strong>12 months.</strong></i></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:10.5pt;\"><strong>References:</strong></span></p><p><span style=\"font-size:10.5pt;\"><strong>Joplingâ€™s handbook of leprosy, 6<sup>th</sup> edition, page no 10</strong></span></p><p><span style=\"font-size:10.5pt;\"><strong>Andrewâ€™s diseases of the skin: clinical dermatology 13<sup>th</sup> edition page no 338, 339, 345</strong></span></p>",
      "correct_choice_id": 143332,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35886,
      "choices": [
        {
          "id": 143339,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1, 2, 4</span></span></span></p>"
        },
        {
          "id": 143340,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1, 3, 4</span></span></span></p>"
        },
        {
          "id": 143341,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2, 3, 4</span></span></span></p>"
        },
        {
          "id": 143342,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1, 2, 3</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chemoprophylaxis for Leprosy should be given to which of the following persons?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sharing the Same Clothes, Towels</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Living with a patient with Leprosy for &gt; 6 Month</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contact of Age more than 2 Years</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contact for more than 20 Hours per Week.</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>",
      "unique_key": "Q8212684",
      "question_audio": null,
      "question_video": null,
      "map_id": 23074,
      "difficulty_level": "intermediate",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 2, 3, 4</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chemoprophylaxis for leprosy should be given to contacts 2, 3 and 4.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Chemoprophylaxis for leprosy should be given to the following contacts:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Being identified as a contact, i.e., a person who has been in <strong>close contact</strong> with the index case for <strong>20 hours (</strong>option 4<strong>) </strong>or<strong> more per week </strong>for<strong> more than 3 months (Option 2)</strong> (Exception is <strong>blanket approach</strong> where no link with an index case needs to be established.)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age: More than 2 years (Option 3);</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> if <strong>younger than 2 years</strong>, the child can be given <strong>SDR</strong> at the <strong>age</strong> of <strong>2</strong>, in <strong>follow-up visits</strong> of <strong>contacts</strong> (if meeting all other inclusion criteria.) </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Consent of the contact obtained</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Depending on the country situation, this can be <strong>written</strong> or <strong>verbal consent</strong>. In the case of children, consent should be obtained from the <strong>parent</strong> or <strong>guardian,</strong> and sometimes an <strong>assent</strong> from the <strong>grown-up children.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sharing</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> the same <strong>clothes and towels,</strong> while a potential <strong>route of transmission</strong>, is <strong>not</strong> generally considered a primary <strong>criterion</strong> for <strong>chemoprophylaxis.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong style=\"font-family:Calibri,sans-serif; font-size:11pt\"><span style=\"font-size:12.0pt\">Rifampicin:</span></strong></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>single dose of 600 mg</strong> kills more than <strong>99%</strong> of the <strong>susceptible organisms</strong> present at the start of treatment, that is as much as <strong>3 to 6 months</strong> of daily treatment with the combination <strong>dapsone plus Clofazimine.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rifampicin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> has become established as a <strong>highly potent bactericidal drug</strong>, and it acts by <strong>inhibiting</strong> the <strong>bacterial DNA dependent RNA polymerase</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Single Dose of Rifampicin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (SDR) is used in <strong>chemoprophylaxis. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chemoprophylaxis must be initiated only <strong>4 weeks after treatment for leprosy</strong> has begun in the <strong>patient</strong>to ensure the <strong>patient is non-infectious</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/screenshot-2024-02-22-094813.jpg\" style=\"height:308px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><strong>Educational Objective&nbsp;</strong></u></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Exclusion Criteria</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Persons with possible signs and/or symptoms of <strong>Leprosy.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Persons with possible signs and/or symptoms of <strong>TB </strong>or<strong> Confirmed </strong>with<strong> TB.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Persons with a history of <strong>Liver </strong>or<strong> Kidney Disorders</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pregnancy</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">; SDR can be <strong>given after the delivery</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Persons who have received <strong>Rifampicin </strong>in the<strong> last two years</strong> e.g. as treatment of TB, leprosy or as prophylaxis (e.g. contact of another index case).</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Persons with history of <strong>Allergy </strong>to<strong> Rifampicin</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Refusal </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">to take<strong> SDR.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Ref</span></u></strong><span style=\"font-size:12.0pt\">: <strong>Jopling&rsquo;s Handbook of Leprosy 6<sup>th</sup> Edition Page no 242</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Leprosy/Hansen disease: Contact Tracing and Post-Exposure ;Prophylaxis </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><a href=\"https://www.who.int/publications/i/item/9789290228073\" style=\"color:#0563c1; text-decoration:underline\">https://www.who.int/publications/i/item/9789290228073</a></span><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"> (Page 23, 24)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051288/\" style=\"color:#0563c1; text-decoration:underline\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051288/</a></span></span></span></p>",
      "correct_choice_id": 143341,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35889,
      "choices": [
        {
          "id": 143351,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1 week </span></span></span></p>"
        },
        {
          "id": 143352,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2 weeks</span></span></span></p>"
        },
        {
          "id": 143353,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3 weeks</span></span></span></p>"
        },
        {
          "id": 143354,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5 weeks</span></span></span><br />\r\n&nbsp;</p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dapsone syndrome in Hansen disease treatment is seen after how many weeks of therapy initiation?</span></span></span></p>",
      "unique_key": "Q8212377",
      "question_audio": null,
      "question_video": null,
      "map_id": 23075,
      "difficulty_level": "difficult",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">D) 5 weeks</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dapsone syndrome, also known as <strong>&quot;five-week dermatitis,&quot;</strong> usually occurs <strong>five</strong> to <strong>six weeks</strong> <strong>after</strong> the <strong>initiation</strong> of <strong>dapsone treatment</strong> in <strong>Hansen&#39;s disease (leprosy</strong>). </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is characterized by symptoms such as <strong>erythroderma, generalized lymphadenopathy, hepatosplenomegaly, fever, </strong>and<strong> hepatitis</strong>, and typically <strong>subsides</strong> upon <strong>cessation</strong> of the drug.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Dapsone syndrome</strong>, a <strong>hypersensitivity reaction </strong>characterized by a range of symptoms including <strong>erythroderma and hepatosplenomegaly</strong>, typically occurs about <strong>five to six weeks</strong> after the initiation of dapsone therapy in the treatment of Hansen&#39;s disease.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: </span></strong><strong><span style=\"font-size:12.0pt\">Jopling&rsquo;s Handbook of Leprosy 6<sup>th</sup> Edition Page No 245</span></strong></span></span></p>",
      "correct_choice_id": 143354,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35892,
      "choices": [
        {
          "id": 143363,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is used to define the Immune Status of the patient. </span></span></span></p>"
        },
        {
          "id": 143364,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a Diagnostic Test. </span></span></span></p>"
        },
        {
          "id": 143365,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a Cell-Mediated Response. </span></span></span></p>"
        },
        {
          "id": 143366,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It may be used for Prognosis.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old patient with a suspected case of leprosy undergoes a lepromin skin test. The test is administered to assess the patient&#39;s type of leprosy and potential response to treatment. Which of the following statements is INCORRECT regarding the lepromin test?</span></span></span></p>",
      "unique_key": "Q1375474",
      "question_audio": null,
      "question_video": null,
      "map_id": 23085,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">B) It is a Diagnostic Test</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The lepromin test is <strong>not </strong>used for the<strong> diagnosis</strong> of leprosy, as it does <strong>not differentiate</strong> between those <strong>infected</strong> and those <strong>who are not</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used primarily for <strong>prognosis</strong> and to determine the <strong>type</strong> of <strong>immune response</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">It is used to define the immune status of the patient</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The lepromin test is used to determine the patient&#39;s <strong>immune response</strong> to <strong>Mycobacterium leprae</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A positive test suggests a <strong>good cell-mediated immune</strong> response, typically seen in <strong>tuberculoid leprosy.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">It is a cell-mediated response</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The lepromin test measures a <strong>delayed-type hypersensitivity</strong> reaction, which is a <strong>cell-mediated immune response</strong> to the <strong>antigens</strong> of <strong>Mycobacterium leprae</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">It may be used for prognosis</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A <strong>positive lepromin test</strong> generally indicates a <strong>better prognosis</strong> and is associated with a <strong>stronger cell-mediated immune</strong> response, which is <strong>typical</strong> of <strong>tuberculoid leprosy</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The lepromin test is used to assess the <strong>immune status</strong> of a patient with leprosy and is <strong>not a diagnostic</strong> test. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It measures the <strong>cell-mediated immune response</strong> and can provide <strong>prognostic information</strong>, with a <strong>positive test indicating</strong> a <strong>better prognosis.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: </span></strong><strong><span style=\"font-size:12.0pt\">Jopling&rsquo;s Handbook of Leprosy 6<sup>th</sup> Edition Page No 11</span></strong></span></span></p>",
      "correct_choice_id": 143364,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35896,
      "choices": [
        {
          "id": 143379,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Rifampicin 450 mg Clofazimine 150 mg Dapsone 50 mg</span></p>"
        },
        {
          "id": 143380,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Rifampicin 600 mg Clofazimine 300 mg Dapsone 100 mg</span></p>"
        },
        {
          "id": 143381,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Rifampicin 450 mg Clofazimine 150 mg Dapsone 100 mg</span></p>"
        },
        {
          "id": 143382,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Rifampicin 300 mg Clofazimine 150 mg Dapsone 50 mg</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 12-year-old child presented with multiple hypopigmented patches on back &amp; lower limb. On examination the patches were hypo aesthetic &amp; bilateral ulnar and lateral popliteal nerves were enlarged. Which of the following drugs and their dosages are to be given on Day 1 of supervised drug administration according to National Leprosy Eradication Programme (NLEP) Guidelines?</span></p>",
      "unique_key": "Q7282389",
      "question_audio": null,
      "question_video": null,
      "map_id": 23086,
      "difficulty_level": "intermediate",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. A) Rifampicin 450 mg Clofazimine 150 mg Dapsone 50 mg</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option A.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:13.5pt;\"><strong>Latest Guidelines for Leprosy: NLEP = WHO (from April 1, 2025)</strong></span></p><p>As of <strong>April 1, 2025</strong>, <strong>India's NLEP has aligned completely with WHO guidelines</strong> for the <strong>diagnosis and treatment of leprosy</strong>. This means that the <strong>same criteria and drug regimens</strong> are now followed globally and in India.</p><p>&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 12-year-old child presenting with multiple hypopigmented and hypo aesthetic patches with bilateral ulnar and popliteal nerves enlarged clinches the diagnosis of <strong>Multi Bacillary Leprosy</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Hence treatment would be with <strong>MB MDT regimen</strong> according to <strong>NLEP Guidelines</strong></span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">According to the <strong>National Leprosy Eradication Programme (NLEP) Guidelines</strong>, for a child aged <strong>9-14 years</strong>, the <strong>Day 1</strong> supervised dose of medication for <strong>Multi-Bacillary (MB) leprosy</strong> includes <strong>Rifampicin 450 mg, Clofazimine 150 mg, and Dapsone 50 mg</strong>.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"margin-left:48px;text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/picture8.jpg\" alt=\"\" width=\"1000\" height=\"740\"></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option B. Rifampicin 600 mg Clofazimine 300 mg Dapsone 100 mg</strong>:</span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Incorrect</strong> because this dosage is for <strong>adults with MB leprosy</strong>, not for children.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The correct dosages of multi-drug therapy for a <strong>child with Multi-Bacillary (MB)</strong> leprosy on <strong>Day 1</strong> of supervised treatment according to <strong>NLEP Guidelines</strong>, which for a child aged <strong>9-14 years</strong> includes <strong>Rifampicin 450 mg, Clofazimine 150 mg, and Dapsone 50 mg</strong>.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Ref</u>: Joplingâ€™s Handbook of Leprosy 6<sup>th</sup> Edition Page No 252</strong></span></p>",
      "correct_choice_id": 143379,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35900,
      "choices": [
        {
          "id": 143395,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dapsone Hypersensitivity Syndrome </span></span></span></p>"
        },
        {
          "id": 143396,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Erythema Nodosum Leprosum </span></span></span></p>"
        },
        {
          "id": 143397,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Lucio Phenomenon </span></span></span></p>"
        },
        {
          "id": 143398,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reversal Reaction</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient of leprosy on multidrug treatment came to OPD after 5 weeks of treatment with rash over the body. On examination he has high grade fever, jaundice, and an itchy rash all over the body. There was no evidence of any red tender nodules over the extremities or elsewhere over the body. What is the likely diagnosis of this patient? </span></span></span></p>",
      "unique_key": "Q9916926",
      "question_audio": null,
      "question_video": null,
      "map_id": 23092,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">A) Dapsone Hypersensitivity Syndrome</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: Dapsone Hypersensitivity Syndrome</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dapsone Hypersensitivity syndrome is a <strong>severe idiosyncratic reaction</strong> that typically occurs about <strong>5 weeks</strong> after the initiation of therapy. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It presents with <strong>fever, rash (usually maculopapular), lymphadenopath</strong>y, and systemic symptoms such as <strong>hepatitis</strong>, which may manifest as <strong>jaundice</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This condition is <strong>dose-independent</strong> and requires <strong>immediate cessation of dapsone</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">Erythema nodosum leprosum (ENL)</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ENL, or <strong>Type II lepra reaction</strong>, presents with <strong>tender red nodules,</strong> systemic involvement like <strong>fever, malais</strong>e, and <strong>enlarged tender nerves</strong>. </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/7.jpg\" style=\"height:401px; width:300px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;&nbsp;<img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/8.jpg\" style=\"height:227px; width:300px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The absence of red tender nodules and nerve tenderness makes ENL less likely in this case.</span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Lucio phenomenon</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lucio phenomenon is a <strong>rare reaction</strong> seen in <strong>diffuse lepromatous leprosy</strong> presenting with <strong>painful erythematous plaques</strong>, typically on the <strong>extremities</strong>, that can progress to <strong>necrosis and ulceration</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It does not typically present with a generalized itchy rash or jaundice.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Reversal reaction (Type I reaction)</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Reversal reaction</span></strong><span style=\"font-size:12.0pt\"> is characterized by the <strong>acute inflammation</strong> of <strong>pre-existing</strong> leprosy <strong>skin lesions</strong> and <strong>nerve enlargement</strong> without systemic symptoms like <strong>fever</strong> or <strong>jaundice.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The pruritic rash and systemic symptoms described are not typical of a reversal reaction.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Dapsone Hypersensitivity syndrome</strong> in a <strong>leprosy patient</strong> who presents with <strong>fever, jaundice</strong>, and a widespread <strong>itchy rash</strong> <strong>without tender nodules</strong> or <strong>nerve enlargement</strong>, approximately <strong>5 weeks</strong> after <strong>starting multidrug therapy</strong>. This serious reaction requires <strong>immediate attention</strong> and <strong>discontinuation of dapsone</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: </span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">IAL Textbook of Leprosy, 2<sup>nd</sup> Edition Chapter 30 Page No 442</span></strong></span></span></p>",
      "correct_choice_id": 143395,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35902,
      "choices": [
        {
          "id": 143403,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3 Drugs are given in the regimen</span></span></span></p>"
        },
        {
          "id": 143404,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treatment Duration is 18 Months</span></span></span></p>"
        },
        {
          "id": 143405,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treatment should be Completed in 18 Months</span></span></span></p>"
        },
        {
          "id": 143406,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follow up Period is 24 Months</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the INCORRECT statement regarding Treatment of a Multi Bacillary Leprosy patient?</span></span></p>",
      "unique_key": "Q3741730",
      "question_audio": null,
      "question_video": null,
      "map_id": 23093,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Treatment Duration is 18 Months</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to the updated guidelines by the <strong>National Leprosy Eradication Programme (NLEP)</strong>, which recommend a treatment duration of <strong>12 months</strong> for <strong>multi-bacillary leprosy</strong>, not 18 months.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">3 drugs are given in the regimen</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>Standard Multi-Drug Therapy (MDT) regimen</strong> for <strong>multi-bacillary (MB) leprosy</strong> involves a <strong>combination</strong> of <strong>three drugs</strong>: <strong>Rifampicin, Dapsone, </strong>and<strong> Clofazimine</strong>.</span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/9.jpg\" style=\"height:251px; width:400px\" /></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option C. </strong>Treatment should be completed in 18 months: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NLEP guidelines <strong>stipulate</strong> a <strong>12-month treatment</strong> course for <strong>MB leprosy</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This course can be completed in <strong>18 months</strong>, otherwise patient is termed as <strong>Defaulter</strong></span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Follow up period is 24 months</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The follow-up period after the completion of treatment for MB leprosy is typically <strong>24 months</strong> to <strong>monitor</strong> for any <strong>signs of relapse</strong> or <strong>late reactions.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>treatment duration</strong> for <strong>multi-bacillary leprosy</strong> according to <strong>NLEP</strong> guidelines is <strong>12 months,</strong> not 18 months, with a <strong>follow-up period</strong> of <strong>24 months post-treatment</strong> to ensure there are <strong>no</strong> <strong>relapses</strong> or <strong>complications</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: </span></strong><strong><span style=\"font-size:12.0pt\">Jopling&rsquo;s Handbook of Leprosy 6<sup>th</sup> Edition Page No 252</span></strong></span></span></p>",
      "correct_choice_id": 143404,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35904,
      "choices": [
        {
          "id": 143411,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Borderline Lepromatous (BL) </span></span></span></p>"
        },
        {
          "id": 143412,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lepromatous Leprosy (LL) </span></span></span></p>"
        },
        {
          "id": 143413,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pure Neuritic Leprosy </span></span></span></p>"
        },
        {
          "id": 143414,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Borderline (BB)</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Foam Cells are seen in Abundance in which type of Leprosy?</span></span></span></p>",
      "unique_key": "Q1497299",
      "question_audio": null,
      "question_video": null,
      "map_id": 23094,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">B) Lepromatous leprosy (LL)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lepromatous leprosy is characterized by numerous <strong>foam cells</strong>, also known as <strong>Virchow&#39;s cells</strong>, which are <strong>lipid-laden macrophages</strong> filled with <strong>Mycobacterium leprae.</strong></span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/10_oTthCEA.jpg\" style=\"height:289px; width:400px\" /></p>\r\n\r\n<p style=\"margin-left:24px; text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Borderline lepromatous (BL<strong>): </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BL leprosy can have <strong>foam cells</strong>, they are <strong>most abundant</strong> in <strong>LL leprosy</strong> where there is <strong>widespread infiltration</strong> of the <strong>skin</strong> with <strong>numerous bacilli</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Pure Neuritic Leprosy:<strong> </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pure Neuritic Leprosy primarily <strong>affects nerves</strong>, and <strong>foam cells</strong> are more typically associated with <strong>cutaneous lesions.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Borderline (BB)</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In BB leprosy, <strong>foam cells</strong> may be present but are not as prominent as in LL leprosy. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BB leprosy has features <strong>between tuberculoid</strong> and <strong>lepromatous leprosy</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Lepromatous leprosy (LL)</strong>&nbsp;is the <strong>form</strong> of <strong>Hansen&#39;s disease</strong> most associated with the presence of <strong>abundant foam cells</strong>, which are <strong>macrophages </strong>filled with<strong> undigested M. leprae</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">These foam cells are indicative of the <strong>multibacillary form</strong> of the <strong>disease</strong> and are used as a <strong>diagnostic histopathological feature</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: </span></strong><strong><span style=\"font-size:12.0pt\">Jopling&rsquo;s Handbook of Leprosy 6<sup>th</sup> Edition Page No 123</span></strong></span></span></p>",
      "correct_choice_id": 143412,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35907,
      "choices": [
        {
          "id": 143423,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Steroids</span></span></span></p>"
        },
        {
          "id": 143424,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azathioprine</span></span></span></p>"
        },
        {
          "id": 143425,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chloroquine</span></span></span></p>"
        },
        {
          "id": 143426,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications is used only for treating patients with Type II Lepra reaction but NOT used in Type I Lepra reaction?</span></span></p>",
      "unique_key": "Q3789175",
      "question_audio": null,
      "question_video": null,
      "map_id": 23095,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">D) Thalidomide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide is particularly <strong>effective</strong> in treating <strong>Type II lepra reactions</strong>, also known as <strong>Erythema Nodosum Leprosum (ENL)</strong>, due to its <strong>potent Anti-Inflammatory</strong> and immunomodulatory effects. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is not used for Type I reactions, which are managed with <strong>steroids</strong> and other <strong>immunosuppressive agents</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Steroids</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Steroids are used in the management of <strong>both Type I and Type II lepra</strong> reactions. They are effective in <strong>reducing inflammation </strong>and<strong> immune reactions</strong> in <strong>both types</strong> of <strong>reactions</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">Azathioprine</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azathioprine may be used as a <strong>steroid-sparin</strong>g <strong>agent</strong> in the treatment of <strong>both Type I</strong> and <strong>Type II lepra reactions,</strong> although it is not the first-line treatment for either.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Chloroquine</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chloroquine, an <strong>antimalarial medication</strong>, has been used in the <strong>treatment</strong> of <strong>Erythema Nodosum Leprosum (ENL)</strong>, which is a <strong>Type II reaction</strong>, but it is also used for <strong>Type I reactions</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thalidomide</strong> is <strong>uniquely</strong> used for <strong>Type II lepra reactions</strong> (<strong>erythema nodosum leprosum)</strong> and is not indicated for Type I lepra reactions. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Thalidomide&#39;s effectiveness</span></strong><span style=\"font-size:12.0pt\"> is based on its ability to <strong>inhibit TNF-alpha</strong>, a <strong>cytokine</strong> involved in the <strong>inflammatory process</strong> of <strong>ENL</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: </span></strong><strong><span style=\"font-size:12.0pt\">Jopling&rsquo;s Handbook of Leprosy 6<sup>th</sup> Edition Page No 217</span></strong></span></span></p>",
      "correct_choice_id": 143426,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35909,
      "choices": [
        {
          "id": 143431,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Foam Cells.</span></span></span></p>"
        },
        {
          "id": 143432,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Granulomas</span></span></span></p>"
        },
        {
          "id": 143433,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Caseous Necrosis</span></span></span></p>"
        },
        {
          "id": 143434,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acantholysis</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the predominant Histological finding in a patient who has Tuberculoid leprosy?</span></span></span></p>",
      "unique_key": "Q3589580",
      "question_audio": null,
      "question_video": null,
      "map_id": 23096,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">B) Granulomas</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The predominant histopathological finding in <strong>tuberculoid leprosy</strong> is well-formed granulomas.</span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/22/11_UZu2bb5.jpg\" style=\"height:241px; width:350px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Granulomas consist of <strong>Lymphocytes</strong>, <strong>Epithelioid cells</strong>, and <strong>Langhan&rsquo;s giant cells</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">These granulomas consist of <strong>collections</strong> of <strong>immune cells</strong> that form as a response to the presence of <strong>Mycobacterium leprae</strong>, indicative of a <strong>robust immune response</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Foam Cells</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Foam cells, or <strong>Virchow&#39;s cells</strong>, are typically found in <strong>lepromatous leprosy,</strong> not tuberculoid leprosy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Caseous Necrosis</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Caseous necrosis is a characteristic feature of t<strong>uberculosis</strong>, not leprosy. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In leprosy, especially the tuberculoid form, <strong>granulomas</strong> are predominantly seen and <strong>caseous necrosis</strong> is only seen with <strong>Nerve granulomas.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Acantholysis</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acantholysis refers to the <strong>loss of connections</strong> between <strong>keratinocytes</strong> in the <strong>epidermis</strong> and is seen in conditions such as <strong>pemphigus vulgaris</strong>, not in leprosy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Granulomas</strong>&nbsp;is the predominant histopathological feature in <strong>tuberculoid leprosy,</strong> reflecting a <strong>strong cell-mediated immune</strong> response that <strong>contains the infection</strong> and <strong>prevents widespread dissemination.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: IAL Textbook of Leprosy, 2<sup>nd</sup> Edition Chapter 14 Page No 136</span></strong></span></span></p>",
      "correct_choice_id": 143432,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35912,
      "choices": [
        {
          "id": 143443,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Seen in Borderline Lepromatous Leprosy and Lepromatous Leprosy patients.</span></span></span></p>"
        },
        {
          "id": 143444,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MDT should be Continued, and Steroids are to be added.</span></span></span></p>"
        },
        {
          "id": 143445,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Underlying Pathogenesis is Increased Cell Mediated Immunity.</span></span></span></p>"
        },
        {
          "id": 143446,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients present with High Grade Fever, Red Tender Nodules over Body.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is FALSE in relation to Type 2 Lepra Reaction?</span></span></p>",
      "unique_key": "Q2032284",
      "question_audio": null,
      "question_video": null,
      "map_id": 23097,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Underlying Pathogenesis is Increased Cell Mediated Immunity.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The pathogenesis of <strong>Type 2 Lepra Reaction (ENL</strong>) is primarily due to <strong>immune complex deposition(Type III hypersensitivity reaction</strong>) and not increased <strong>cell-mediated immunity</strong>, which is more characteristic of <strong>Type 1 reactions</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Seen in Borderline Lepromatous Leprosy and Lepromatous Leprosy patients</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type 2 Lepra Reaction, also known as <strong>Erythema Nodosum Leprosum (ENL),</strong> is typically seen in patients with <strong>Borderline Lepromatous Leprosy</strong> and <strong>Lepromatous Leprosy</strong>, which are at the <strong>multibacillary end</strong> of the leprosy spectrum.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">MDT should be continued, and Steroids are to be added</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">During a Type 2 reaction, the mainstay treatment includes the <strong>continuation of Multi-Drug Therapy</strong> (MDT) for leprosy along with the addition of <strong>steroids</strong> to manage the inflammatory reaction.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Patients present with High grade fever, Red Tender nodules over body</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of ENL includes systemic symptoms such as <strong>high-grade fever and red tender nodules</strong>, known as erythema nodosum leprosum.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Type 2 Lepra Reaction (Erythema Nodosum Leprosum</strong>) is associated with <strong>immune complex deposition</strong> rather than <strong>increased cell-mediated immunity</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It presents with <strong>systemic symptoms</strong> and <strong>cutaneous manifestations</strong> requiring the <strong>continuation </strong>of<strong> MDT</strong> and the <strong>addition</strong> of <strong>anti-inflammatory treatment</strong>, typically <strong>steroids.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: IAL Textbook of Leprosy, 2<sup>nd</sup> Edition Chapter 29 Page No 424</span></span></strong></p>",
      "correct_choice_id": 143445,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35914,
      "choices": [
        {
          "id": 143451,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">Pure Neuritic</span></span></span></p>"
        },
        {
          "id": 143452,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">Borderline Lepromatous</span></span></span></p>"
        },
        {
          "id": 143453,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">Borderline Tuberculoid</span></span></span></p>"
        },
        {
          "id": 143454,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">Indeterminate</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">A 36-year-old male presented multiple hypopigmented patches all over the body which are distributed almost symmetrically. On examination multiple thickened nerves almost symmetrically enlarged are palpable. What type of leprosy does the patient has?</span></span></span></p>",
      "unique_key": "Q9830563",
      "question_audio": null,
      "question_video": null,
      "map_id": 23098,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">B) Borderline Lepromatous</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of <strong>almost symmetrically distributed</strong> <strong>hypopigmented skin patches</strong> over body and </span><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">multiple thickened nerves</span></strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"> almost symmetrically enlarged </span><span style=\"font-size:12.0pt\">suggests <strong>Borderline Lepromatous leprosy.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Pure Neuritic</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pure Neuritic leprosy presents with <strong>nerve involvement</strong> without the skin lesions, which is not the case in the scenario described.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Borderline tuberculoid</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Borderline tuberculoid leprosy would typically present with <strong>fewer </strong>and<strong> asymmetric skin lesions</strong>, and while nerve involvement is common, it does not typically present with symmetry as described.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Indeterminate</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Indeterminate leprosy is an <strong>early</strong> and <strong>unstable form</strong>, often presenting as a <strong>single </strong>or a<strong> few hypopigmented macules</strong> without definite nerve enlargement.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Borderline Lepromatous leprosy</strong> as a type <strong>characterized</strong> by <strong>multiple almost symmetrically</strong> distributed <strong>skin lesions</strong> and </span><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">multiple thickened nerves</span></strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"> almost <strong>symmetrically enlarged</strong></span><span style=\"font-size:12.0pt\">.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: IAL Textbook of Leprosy, 2<sup>nd</sup> Edition Chapter 15 Page No 244</span></strong></span></span></p>",
      "correct_choice_id": 143452,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35916,
      "choices": [
        {
          "id": 143459,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Teratogenic Drug</span></span></span></p>"
        },
        {
          "id": 143460,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Causes Peripheral Neuropathy</span></span></span></p>"
        },
        {
          "id": 143461,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Useful in Type 2 Lepra Reaction</span></span></span></p>"
        },
        {
          "id": 143462,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Also Useful in Type 1 Lepra Reaction</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identify the FALSE statement among the following options in relation to Thalidomide in the treatment of leprosy?</span></span></span></p>",
      "unique_key": "Q8929123",
      "question_audio": null,
      "question_video": null,
      "map_id": 23099,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">D) Also Useful in Type 1 Lepra reaction</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide is not typically used in the treatment of Type 1 Lepra reactions, also known as <strong>reversal reactions</strong>, which are <strong>managed</strong> with <strong>steroids</strong> and other <strong>immunosuppressive therapies</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Teratogenic drug</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide is <strong>highly teratogenic</strong> and can cause <strong>severe birth defects</strong>, which is why its use is highly regulated and <strong>contraindicated during pregnancy.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">Causes Peripheral neuropathy</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A known side effect of thalidomide is <strong>peripheral neuropathy</strong>, which can be a significant complication requiring <strong>monitoring</strong> during treatment.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Useful in Type 2 Lepra reaction</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide is particularly effective in treating <strong>Type 2 Lepra Reactions</strong>, also known as <strong>Erythema Nodosum Leprosum (ENL)</strong>, due to its <strong>Anti-Inflammatory Properties</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thalidomide</strong> is a <strong>Teratogenic Drug</strong> used in the treatment of <strong>Type 2 Lepra Reactions (Erythema Nodosum</strong> <strong>Leprosum</strong>) and can cause <strong>peripheral neuropathy</strong> as a <strong>side effect</strong>, but it is not used for Type 1 Lepra reactions. </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: </span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IAL Textbook of Leprosy, 2<sup>nd</sup> Edition Chapter 30 Page No 472</span></span></strong></p>",
      "correct_choice_id": 143462,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35919,
      "choices": [
        {
          "id": 143471,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dapsone</span></span></span></p>"
        },
        {
          "id": 143472,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide</span></span></span></p>"
        },
        {
          "id": 143473,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rifampicin</span></span></span></p>"
        },
        {
          "id": 143474,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clofazimine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which among the following medications can cause orange discolouration of urine?</span></span></span></p>",
      "unique_key": "Q9156899",
      "question_audio": null,
      "question_video": null,
      "map_id": 23100,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">C) Rifampicin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rifampicin can cause <strong>orange-red discoloration</strong> of <strong>bodily fluids</strong>, including <strong>urine, feces, sweat, saliva, </strong>and<strong> tears</strong>. This is a <strong>benign</strong> and <strong>well-recognized side effect</strong> of the <strong>medication</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Dapsone</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dapsone does not typically cause orange discoloration of bodily fluids. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It can cause <strong>hemolysis</strong> and <strong>methemoglobinemia</strong> as <strong>side effects</strong>, especially in patients with <strong>Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">Thalidomide</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide does not cause orange discoloration of urine; its significant side effects include <strong>teratogenicity </strong>and <strong>peripheral neuropathy</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Clofazimine</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clofazimine can cause <strong>skin </strong>and<strong> bodily fluids </strong>to turn<strong> pink </strong>to<strong> brownish black</strong>, but it is not typically associated with orange discoloration of urine.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rifampicin</strong> can cause <strong>orange-red discoloration </strong>of <strong>bodily fluids</strong>, including <strong>urine, </strong>which is a <strong>harmless side effect</strong> and does <strong>not indicate harm</strong> or the need to stop therapy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: IAL Textbook of Leprosy, 2<sup>nd</sup> Edition Chapter 30 Page No 442</span></strong></span></span></p>",
      "correct_choice_id": 143473,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35923,
      "choices": [
        {
          "id": 143487,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tumour Necrosis Factor Alpha (TNF-&alpha;)</span></span></span></p>"
        },
        {
          "id": 143488,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Interferon Gamma (IFNâ€</span><span style=\"font-size:12.0pt\">&gamma;</span><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">)</span></span></span></p>"
        },
        {
          "id": 143489,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Interleukin 10 (IL-10)</span></span></span></p>"
        },
        {
          "id": 143490,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Transforming Growth Factor Beta (TGF&beta;)</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is associated with inflammatory manifestations of Erythema Nodosum Leprosum? </span></span></p>",
      "unique_key": "Q5254854",
      "question_audio": null,
      "question_video": null,
      "map_id": 23101,
      "difficulty_level": "intermediate",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">A) Tumour Necrosis Factor Alpha (TNF-&alpha;)</span></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TNF-&alpha; is a <strong>cytokine</strong> that plays a key role in the pathogenesis of <strong>Erythema Nodosum Leprosum (ENL), </strong>an <strong>immune-mediated complication</strong> of <strong>leprosy</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">TNF-&alpha;</span></strong><span style=\"font-size:12.0pt\"> is associated with the <strong>inflammatory cascade</strong> that leads to the <strong>formation</strong> of the <strong>painful nodules </strong>characteristic of <strong>ENL</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><strong><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"> B. Interferon Gamma (IFNâ€</span></strong><strong><span style=\"font-size:12.0pt\">&gamma;</span></strong><strong><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">)</span></strong><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While IFN-&gamma; is a <strong>pro-inflammatory cytokine</strong> involved in the immune response against Mycobacterium leprae, it is not specifically implicated in the pathogenesis of ENL as prominently as TNF-&alpha;.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Interleukin 10 (IL-10)</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IL-10 is an <strong>anti-inflammatory cytokine</strong>, and while it plays a role in the <strong>immune response</strong>, it is not primarily responsible for the inflammatory manifestations seen in ENL.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Transforming growth factor beta (TGF -&beta;)</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TGF-&beta; is generally considered an <strong>anti-inflammatory</strong> and <strong>regulatory cytokine</strong> and is not typically associated with the inflammatory symptoms of ENL.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Tumour Necrosis Factor Alpha (TNF-&alpha;)</strong> is the <strong>cytokine</strong> closely associated with the <strong>inflammatory</strong> manifestations of <strong>Erythema Nodosum Leprosum</strong> in <strong>leprosy</strong>, and management often includes medications that <strong>modulate </strong>the activity of<strong> TNF-&alpha;.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref:</span></u></strong><strong> </strong><strong><span style=\"font-size:12.0pt\">Jopling&rsquo;s Handbook of Leprosy 6<sup>th</sup> Edition Page No 220</span></strong></span></span></p>",
      "correct_choice_id": 143487,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35925,
      "choices": [
        {
          "id": 143495,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Isoniazid</span></span></span></p>"
        },
        {
          "id": 143496,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rifampicin</span></span></span></p>"
        },
        {
          "id": 143497,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ethambutol</span></span></span></p>"
        },
        {
          "id": 143498,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ofloxacin </span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which among the following is a anti tubercular medication which is also a most potent anti leprotic drug?</span></span></p>",
      "unique_key": "Q8273404",
      "question_audio": null,
      "question_video": null,
      "map_id": 23102,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">B) Rifampicin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rifampicin is not only an important drug for treating <strong>tuberculosis</strong>, but it is also considered the <strong>most potent</strong> anti-leprotic medication. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is an <strong>essential component</strong> of the <strong>Multi-Drug Therapy (MDT)</strong> for <strong>leprosy</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Isoniazid</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While isoniazid is a key component of the <strong>anti-tubercular regimen</strong>, it is not the most potent drug against Mycobacterium leprae, the causative agent of leprosy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong><span style=\"font-size:12.0pt\">Ethambutol</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ethambutol is used as part of the treatment for <strong>tuberculosis</strong>, but it does not have the same level of potency against Mycobacterium leprae as rifampicin.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Ofloxacin</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ofloxacin is a <strong>fluoroquinolone</strong> antibiotic that can be used in the treatment of <strong>leprosy</strong>, particularly in cases of <strong>drug resistance</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">However, it is <strong>not as potent</strong> as <strong>rifampicin </strong>in the <strong>anti-leprotic regimen</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rifampicin</strong>&nbsp;is the <strong>most potent anti-leprotic drug </strong>that is also used in the treatment of <strong>tuberculosis</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a <strong>corner stone</strong> <strong>drug</strong> in the <strong>Multi-Drug Therapy (MDT)</strong> for <strong>leprosy</strong> due to its <strong>bactericidal</strong> action against Mycobacterium leprae.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: IAL Textbook of Leprosy, 2<sup>nd</sup> Edition Chapter 31 Page No 449</span></strong></span></span></p>",
      "correct_choice_id": 143496,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35927,
      "choices": [
        {
          "id": 143503,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rifampicin</span></span></span></p>"
        },
        {
          "id": 143504,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dapsone</span></span></span></p>"
        },
        {
          "id": 143505,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clofazimine</span></span></span></p>"
        },
        {
          "id": 143506,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ofloxacin </span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which among the following is a anti leprotic drug which is also useful in treatment of Type 2 lepra reaction?</span></span></span></p>",
      "unique_key": "Q5227055",
      "question_audio": null,
      "question_video": null,
      "map_id": 23103,
      "difficulty_level": "intermediate",
      "subjects_id": [
        18
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">C) Clofazimine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clofazimine has <strong>both anti-leprotic </strong>and<strong> anti-inflammatory</strong> properties. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is used in the <strong>treatment</strong> of <strong>leprosy</strong> and has a role in <strong>managing</strong> <strong>Type 2 lepra reactions</strong> due to its <strong>ability</strong> to <strong>reduce inflammation</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\">Rifampicin</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While rifampicin is a <strong>potent anti-leprotic drug</strong> used in <strong>multi-drug therapy (MDT)</strong> for leprosy, it is not specifically used for the treatment of Type 2 lepra reaction (Erythema Nodosum Leprosum, ENL).</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">Dapsone</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dapsone is an <strong>anti-leprotic drug</strong> used in <strong>MDT</strong> for <strong>leprosy</strong>, but it is not the treatment of choice for Type 2 lepra reactions. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is mainly used for its <strong>antibacterial effects</strong> against Mycobacterium leprae.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">Ofloxacin</span><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ofloxacin is used as a <strong>second-line agent</strong> for the treatment of <strong>leprosy</strong>, particularly in cases of <strong>drug resistance</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">However, it is not typically used for the treatment of Type 2 lepra reactions.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Clofazimine</strong> is an <strong>anti-leprotic</strong> <strong>medication</strong> that is also <strong>beneficial</strong> in the treatment of <strong>Type 2 lepra</strong> reactions due to its <strong>anti-inflammatory</strong> <strong>effects</strong>, in addition to its role in the <strong>multi-drug therapy</strong> for <strong>leprosy</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Jopling&rsquo;s Handbook of Leprosy 6<sup>th</sup> Edition Page No 211</span></span></strong></p>",
      "correct_choice_id": 143505,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}